Preclinical evaluation of a liposome-encapsulated formulation of cisplatin in clinically normal dogs

American Journal of Veterinary Research

Volumn 65, Issue 11, 2004, Pages 1474-1478

  Marr, Amanda K ^a   Kurzman, Ilene D ^a,b   Vail, David M ^a,b,c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATROPINE; CISPLATIN; DEXAMETHASONE SODIUM PHOSPHATE; DIPHENHYDRAMINE; FAMOTIDINE; LIPOSOME; ONDANSETRON;

ANAPHYLAXIS; ANIMAL EXPERIMENT; ARTICLE; BLOOD ANALYSIS; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; BRADYCARDIA; CLINICAL PROTOCOL; CLINICAL STUDY; CONTROLLED STUDY; DEFECATION; DOG; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG INFUSION; DRUG SAFETY; ENCAPSULATION; EVALUATION; FEMALE; HYDRATION; HYPEREMIA; LETHARGY; MAXIMUM TOLERATED DOSE; MONOCYTOSIS; MUSCLE WEAKNESS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PANCYTOPENIA; PHYSICAL EXAMINATION; TACHYPNEA; THROMBOCYTOPENIA; UREMIA; URINALYSIS; URTICARIA; VOMITING;

ANIMALS; BLOOD CHEMICAL ANALYSIS; BODY CONSTITUTION; CISPLATIN; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HEMATOLOGIC TESTS; LIPOSOMES; MAXIMUM TOLERATED DOSE; URINALYSIS;

ANIMALIA; CANIS FAMILIARIS;

EID: 9444294516     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2004.65.1474     Document Type: Article

References (23)

1. Dernell WS, Straw RC, Withrow SJ. Tumors of the skeletal system. In: Withrow SJ, MacEwen EG, eds. Small animal clinical oncology. 3rd ed. Philadelphia: WB Saunders Co, 2001;378-417.
2. Malawer MM, Link MP, Donaldson SS. Sarcomas of bone. In: Devita VT, Hellman S, Rosenberg SA, eds. Cancer principles and practice of oncology. 5th ed. Philadelphia: Lippincott-Raven Co, 1997; 1789-1852.
3. Chun R, Garrett L, MacEwen EG. Cancer chemotherapy In: Withrow SJ, MacEwen EG, eds. Small animal clinical oncology. 3rd ed. Philadelphia: WB Saunders Co, 2001;92-118.
4. Hacker MP. Toxicity of platinum-based anticancer drugs. In: Powis G, Hacker MP, eds. The toxicity of anticancer drugs. New York: McGraw-Hill Book Co, 1991;82-97.
5. Bergman PJ, MacEwen EG, Kurzman ID, et al. Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993). J Vet Intern Med 1996;10:76-81.
6. McKeage MJ, Mistry P, Ward J, et al. A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration. Cancer Chemother Pharmacol 1995;36:451-458.
7. Schilder RJ, LaCreta FP, Perez RP, et al. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and 8 schedule. Cancer Res 1994; 54:709-717.
8. Working PK, Newman MS, Sullivan T, et al. Comparative intravenous toxicity of cisplatin solution and cisplatin encapsulated in long-circulating, pegylated liposomes in cynomolgus monkeys. Toxicol Sci 1998;46:155-165.
9. Thamm DH, Vail DM. Preclinical evaluation of a sterically stabilized liposome-encapsulated cisplatin in clinically normal cats. Am J Vet Res 1998;59:286-289.
10. Boulikas T. Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts. Oncol Rep 2004; 12:3-12.
11. Boulikas T, Stathopoulus GP, Volakakis N, et al. Systemic Lipoplatin infusion results in preferential tumor uptake in patients. Ann Oncol 2004;15:in press.
12. Devarajan P, Tarabishi R, Mishra J, et al. Low renal toxicity of Lipoplatin compared to cisplatin in animals. Oncol Rep 2004;12:in press.
13. Boulikas T, Stathopoulos GP, Deliconstantinos G, et al. Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): a phase I study. Br J Cancer 2004;vol:in press.
14. Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level. Oncol Rep 2003;10:1663-1682.
15. Ogilvie GK, Krawiec DR, Gelberg HB, et al. Evaluation of a short-term saline diuresis protocol for the administration of cisplatin. Am J Vet Res 1988;49:1076-1078.
16. Straw RC, Withrow SJ, Richter SL, et al. Amputation and cisplatin for treatment of canine osteosarcoma. J Vet Intern Med 1991; 5:205-210.
17. National Research Council. Guide for the care and use of laboratory animals. Washington, DC: National Academy Press, 1996;8-116.
18. Uziely B, Jeffers S, Isacson R, et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995;13:1777-1785.
19. Vail DM, Kravis LD, Cooley AJ, et al. Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors. Cancer Chemother Pharmacol 1997;39:410-416.
20. Vail DM, Chun R, Thamm DH, et al. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model. Clin Cancer Res 1998;4:1567-1571.
21. Skubitz KM, Skubitz AP. Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil). Anticancer Drugs 1998;9:45-50.
22. Page R, Matus RE, Leifer CE, et al. Cisplatin, a new antineoplastic drug in veterinary medicine. J Am Vet Med Assoc 1985;186:288-290.
23. Knapp DW, Richardson RC, Bonney PL, et al. Cisplatin therapy in 41 dogs with malignant tumors. J Vet Intern Med 1988;2:41-46.